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Abstract
Background:  Limited information is available on the effects of progestins on breast cancer
progression and metastasis. Cell migration and invasion are central for these processes, and require
dynamic cytoskeletal and cell membrane rearrangements for cell motility to be enacted.
Methods: We investigated the effects of progesterone (P), medroxyprogesterone acetate (MPA),
drospirenone (DRSP) and nestorone (NES) alone or with 17β-estradiol (E2) on T47-D breast
cancer cell migration and invasion and we linked some of these actions to the regulation of the
actin-regulatory protein, moesin and to cytoskeletal remodeling.
Results: Breast cancer cell horizontal migration and invasion of three-dimensional matrices are
enhanced by all the progestins, but differences are found in terms of potency, with MPA being the
most effective and DRSP being the least. This is related to the differential ability of the progestins
to activate the actin-binding protein moesin, leading to distinct effects on actin cytoskeleton
remodeling and on the formation of cell membrane structures that mediate cell movement. E2 also
induces actin remodeling through moesin activation. However, the addition of some progestins
partially offsets the action of estradiol on cell migration and invasion of breast cancer cells.
Conclusion: These results imply that P, MPA, DRSP and NES alone or in combination with E2
enhance the ability of breast cancer cells to move in the surrounding environment. However, these
progestins show different potencies and to some extent use distinct intracellular intermediates to
drive moesin activation and actin remodeling. These findings support the concept that each
progestin acts differently on breast cancer cells, which may have relevant clinical implications.
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Background
Hormone replacement therapy (HRT) is used to relieve
menopausal symptoms and to protect postmenopausal
women from osteoporosis [1]. Progestins are required in
HRT in women to prevent an inappropriate estrogen-
dependent endometrial proliferation. A variety of proges-
terone receptor agonists, including natural progesterone
(P) or synthetic progestins are commonly used in HRT
regimens [2]. However, different clinical trials, particu-
larly the Million Women Study and the Women's Health
Initiative trial, have reported increases in breast cancer risk
associated with progestin use in HRT [3-5], suggesting a
deleterious role of progestins on breast cancer.
The pharmacological properties of progestins vary
depending on the parent molecule from which they are
derived, leading to considerable variations of the full spec-
trum of biological activities [2,6]. For instance, beyond
the obvious progestogenic activity, medroxyprogesterone
acetate (MPA), a derivative of 17-hydroxyprogesterone, is
also endowed with glucocorticoid activity [2].
These pharmacological discrepancies may account for the
diverse impact of progestins on breast cancer develop-
ment and progression. For instance, the French cohort
study as well as the E3N-EPIC cohort study show that con-
tinuous-combined HRT with synthetic progestins is asso-
ciated with an increased relative risk of breast cancer in
postmenopausal women, but this is not found with HRT
containing natural progesterone [7,8]. Hence it would be
clinically important to be able to differentiate the effects
on breast cells of the different progestins used for HRT.
In the past few years progestins with improved receptor-
selectivity profiles have been introduced into clinical prac-
tice. Drospirenone (DRSP), a progestogen derived from
spirolactone, is characterized by significant anti-andro-
genic and anti-minineralocorticoid activities [9]. Due to
this, DRSP administration in HRT helps to prevent
sodium and water retention as well as body weight
increases in normotensive post-menopausal women and
to decrease blood pressure in patients with mild hyperten-
sion [10]. Another new progestin with specific character-
istics is nestorone (NES), a 19-nor derivative of
progesterone. NES is characterized by a strong progesta-
tional activity, combined with a complete lack of andro-
genic, estrogenic, and glucocorticoid-like activities. This
makes the compound well-tolerated and devoid of side
effects in clinical practice [11].
The main cause of morbidity and mortality in breast can-
cer patients is the spread to the lymph nodes and to dis-
tant organs of tumor cells [12,13]. While a lot is known on
the effects and mechanisms of action of progesterone on
breast cancer cell proliferation [14-16], limited informa-
tion is available on the impact on cell migration and inva-
sion. Moreover, the actions of the new progestins (such as
DRSP or NES) on breast cancer have not been investi-
gated.
Cell migration and invasion are based on a complex and
dynamic set of morphological cellular changes, primarily
including the reorganization of the actin cytoskeleton
[17]. During cell movement, the cytoskeletal actin fibres
are dynamically remodelled to provide the structural plat-
form for the development of membrane protrusions such
as filopodia and lamellipodia which are implicated in the
adhesion to the extracellular matrix and in the generation
of the cell's locomotive force [18].
This process is regulated by several intermediates, includ-
ing the ezrin/radixin/moesin (ERM) family of actin-bind-
ing proteins [19]. We recently showed that 17β-estradiol
(E2) leads to dynamic rearrangements of the actin
cytoskeleton and promotes cell migration via the activa-
tion of moesin in human endothelial cells [20], suggest-
ing that the ERM protein-mediated actin remodeling
represents a privileged target of sex steroids for the control
of cell movement.
In this manuscript we investigate the differential effects of
natural progesterone and of the synthetic progestins MPA,
DRSP and NES, alone or in combination with E2, on
moesin activation, actin remodeling, cell migration and
invasion in T47-D breast cancer cells.
Methods
Cell cultures and treatments
T47-D and MCF-7 breast cancer cells were incubated in
DMEM (GIBCO) containing 10% fetal calf serum (FCS)
and 0.2 UI/mL insulin, L-glutamine, penicillin and strep-
tomycin under a 5% CO2 atmosphere at 37°C. MDA-MB-
468 breast cancer cells were incubated in L-15 medium
(Leibovitz)(GIBCO) containing 10% fetal calf serum
(FCS) and L-glutamine, penicillin and streptomycin.
Before treatments, cells were kept 48 hours in DMEM con-
taining steroid-deprived FBS. Before experiments investi-
gating non-transcriptional effects, the cells were kept in
DMEM containing no FBS for 8 hours. Whenever an
inhibitor was used, the compound was added 30 minutes
before starting the treatments. Progesterone, medroxypro-
gesterone acetate, 17β-estradiol, PTX, Y-27632, PD98059
and wortmannin were from Sigma-Aldrich (Saint-Louis,
MO). Drospirenone was a kind gift of Dr. Heiner Fritze-
meier (Bayer Schering Pharma, Berlin, Germany), Nestor-
one was provided by Dr. R. Sitruk-Ware and ORG 31710
was a kind gift of Dr. Lenus Kloosterboer, from Organon
Akzo Nobel (Oss, The Netherlands).BMC Cancer 2008, 8:166 http://www.biomedcentral.com/1471-2407/8/166
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Cell immunofluorescence
T47-D breast cancer cells were grown on coverslips and
exposed to treatments. The cells were fixed with 4% para-
formaldehyde for 30 min and permeabilized with 0.1%
Triton for 5 min. Blocking was performed with PBS con-
taining 1% bovine serum albumin for 30 min. Then cells
were incubated with Texas Red-phalloidin (Sigma) for 10
min. After washing the nuclei were counterstained with 4'-
6-diamidino-2-phenylindole (DAPI) (Sigma) and
mounted with Vectashield mounting medium (Vector
Laboratories, Burlingame, CA). Immunofluorescence was
visualized using an Olympus BX41 microscope and
recorded with a high-resolution DP70 Olympus digital
camera. Cell membrane thickness and the gray level of
extracellular area, cell membrane as well as cytoplasm
were quantitated using Leica QWin image analysis and
image processing software (Leica Microsystems, Wetzlar,
Germany).
Immunoblottings
Cells were harvested in lysis buffer including100 mM Tris-
HCl (pH 6.8), 4% SDS, 20% glycerol, 1 mM Na3VO4, 1
mM NaF, and 1 mM PMSF. Cell lysates were separated by
SDS-PAGE. The antibodies used were: moesin (clone 38,
Transduction Laboratories, Lexington, KY), Thr558-P-
moesin (sc-12895, Santa Cruz Biotechnology, Santa Cruz,
CA). Primary and secondary Abs were incubated with the
membranes with standard technique [21]. Immunodetec-
tion was accomplished using enhanced chemilumines-
cence.
Transfection experiments
Plasmids for CMV human progesterone receptor A (hPR-
A, # 95) and B (hPR-A, # 90) were provided by Dean P.
Edwards (Baylor college of medicine, USA). Both plas-
mids (15 μg) were transfected into MDA-MB-468 breast
cancer cells using the Lipofectamine (Invitrogen) accord-
ing to the manufacturer's instructions. Cells (60–70%
confluent) were treated 48 h after transfection and pre-
pared according to the experiments to be performed.
Validated antisense phosphorotioate oligonucleotides (S-
modified) (PONs) complementary to the 1–15 position
of the human moesin gene coding region were obtained
from Dharmacon. The sequence was 5'-TACGGGTTTT-
GCTAG-3' for moesin antisense PON. The complemen-
tary sense PON was used as control (5'-
CTAGCAAAACCCGTA-3'). Transfections were performed
on subconfluent T47-D cells. PONs were resuspended in
serum-free medium with Lipofectamine (Invitrogen) and
added to the culture medium every 12 h at the final con-
centration of 4 μM. Every 24 h, cells were washed and
fresh medium supplemented with 4 μM PONs was added.
Moesin silencing was assessed through protein analysis up
to 48 h after transfection.
Cell migration assays
Cell migration was assayed with razor scrape assays as pre-
viously described [20]. Briefly, a razor blade was pressed
through the confluent T47-D breast cancer cell monolayer
into the plastic plate to mark the starting line. T47-D cells
were swept away on one side of that line. Cells were
washed, and 2.0 mL of DMEM containing steroid-
deprived FBS and gelatin (1 mg/mL) were added. Cyto-
sine  β-D-arabinofuranoside hydrochloride (Sigma) (10
μM), a selective inhibitor of DNA strand separation which
does not inhibit RNA synthesis was used 1 h before the
test substance was added. Migration was monitored for 48
hours. Every 12 h fresh medium and treatment were
replaced. Cells were digitally imaged and migration dis-
tance was measured by using phase-contrast microscopy.
Cell invasion assays
Cell invasion were assayed following the standard
method by using the BD BioCoatTM Growth Factor
Reduced (GFR) Matrigel™ Invasion Chamber (BD Bio-
science, USA). In brief, after rehydrating the GFR Matrigel
inserts, the test substance was added to the wells. An equal
number of Control Inserts (no GFR Matrigel coating) were
prepared as control. 0.5 mL of T47-D cell suspension (2.5
× 104 cells/mL) was added to the inside of the inserts. The
chambers were incubated for 24 h at 37°C, 5% CO2
atmosphere. After incubation, the non-invading cells were
removed from the upper surface of the membrane using
cotton tipped swabs. Then the cells on the lower surface of
the membrane were stained with Diff-Quick stain. The
invading cells were observed and photographed under the
microscope at 100× magnification. Cells were counted in
the central field of triplicate membranes. The invasion
index was calculated as the % invasion test cell/% inva-
sion control cell.
Statistical analysis
All values are expressed as mean ± SD. Statistical differ-
ences between mean values were determined by ANOVA,
followed by the Fisher's protected least significance differ-
ence (PLSD).
Results
Effects of P, MPA, DRSP and NES on the actin 
cytoskeleton
Our first objective was to identify the effects of P, MPA,
DRSP and NES on the spatial organization of actin fibers.
We thus exposed steroid- and serum-deprived T47-D
(ER+/PR+) breast cancer cells to these compounds and
stained the actin cytoskeleton with phalloidin linked to a
fluorescent dye (Texas Red). Based on the evidence that P,
MPA and DRSP have comparable binding affinities for
progesterone receptor (PR), while NES is about a 100-fold
more effective than P in binding to PR [11], we used a
100-fold lower concentration of NES than other three pro-BMC Cancer 2008, 8:166 http://www.biomedcentral.com/1471-2407/8/166
Page 4 of 14
(page number not for citation purposes)
gestins. At baseline, actin fibers were arranged longitudi-
nally through the major axis of T47-D cells, which
displayed regular cell borders (Fig. 1). In the presence of
any of the four progestins (P, MPA, DRSP all 100 nM;
NES, 1 nM), the vast majority of breast cancer cells dis-
played visible changes of actin fibers organization (within
10 to 15 min), with a rapid actin concentration at the cell
membrane (Fig. 1). This was associated with a significant
increase of the thickness of the cell membrane and of its
fluorescence intensity, quantified by analyzing the pixel
intensity including the cell membrane as well as the adja-
cent intra- and extra-cellular space (Table 1). Within the
same time frame, cell membrane structures involved in
cell adhesion and movement, including ruffles, focal
adhesion complexes and pseudopodia were formed (Fig.
1). This process was transient, with actin fibers going back
to the basal arrangement within 30 minutes, and was
blocked by the PR antagonist ORG 31710 (1 μM), indicat-
ing the involvement of PR (Fig. 1).
Effects of P, MPA, DRSP and NES on actin remodeling in 
the presence of E2
E2 (10 nM) rapidly induced actin rearrangement in T47-
D breast cancer cells, consistent with its action on
Progestins induce a rapid rearrangement of the actin cytoskeleton in T47-D cells Figure 1
Progestins induce a rapid rearrangement of the actin cytoskeleton in T47-D cells. T47-D cells were treated with P, 
MPA, DRSP (all 100 nM) or NES (1 nM) for 10, 15 or 30 minutes, in the presence or absence of the pure PR antagonist ORG 
31710 (1 μM). Immunofluorescent staining of actin (in red) reveals the spatial modifications of actin fibers through the time-
course and the formation of specialized cell membrane structures (yellow arrows indicate longitudinal actin fibers, green 
arrows show pseudopodia, light blue arrows indicate ruffles). Nuclei are counterstained in blue.
CON P 15’ P 30’ P+ ORG
CON MPA 10’ MPA 15’ MPA 30’ MPA+ORG
CON DRSP 10’ DRSP 15’ DRSP 30’ DRSP+ORG
CON NES 10’ NES 15’ NES 30’ NES+ORG
P 10’BMC Cancer 2008, 8:166 http://www.biomedcentral.com/1471-2407/8/166
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endothelial cells [20]. Each progestin, when added to E2,
did not significantly change the effect of E2 itself,
although the cells often display a somewhat more evident
rearrangement of actin fibers (as shown by the quantifica-
tion of the mean thickness and intensity of cell mem-
brane, Table 1) and cell membrane structures formation
as compared to treatment with the progestin alone (Fig.
2). The effect of the addition of the progestins to E2 was
reduced by the PR antagonist ORG 31710 (1 μM) but not
by the ER antagonist ICI 182,780 (100 nM) (Fig. 2).
Likewise, in ER/PR positive MCF-7 breast cancer cells, P
and MPA (both 100 nM) also provoked the rapid actin
reorganization in the absence or presence of E2 (10 nM),
which were indicated by the translocation of actin
towards cell membrane and by the obvious formation of
lamellipodia (Fig. 3, Table 1). However, in MDA-MB-468
ER-/PR- breast cancer cells, the same compounds failed to
induce actin cytoskeleton remodeling (Fig. 3, Table 1).
When MDA-MB-468 cells were transfected with plasmids
encoding PRA and PRB, they became able to respond to
progestin exposure with actin rearrangement (Fig. 3, Table
1), confirming the central role of PR.
Comparative effects of P, MPA, DRSP and NES on the 
actin-regulatory protein, moesin
Treatment of T47-D cells with P, MPA, DRSP (all 100 nM)
or NES (1 nM) resulted in rapid increases of Thr558-phos-
phorylation of moesin (which corresponds to activation)
[22], with a first visible effect from 2 minutes, a phospho-
rylation peak at 15 minutes, and a progressive decline to
basal levels between 30 minutes and 2 hours, which is
time-consistent with the kinetics of actin rearrangement
(Fig. 4A–D). The amount of phosphorylated moesin was
related to the concentration of the compounds (Fig. 4E–
H). In parallel, the cell content of wild-type moesin did
not change during this time frame (Fig. 4A–H).
When bioequivalent amounts of P, MPA, DRSP (all 100
nM) or NES (1 nM) were administered to T47-D cells, vis-
ible differences in moesin Thr558-phosphorylation were
seen, with MPA inducing the strongest activation and
DRSP the weakest (Fig. 5A). In order to more precisely
compare the potency of each progestin on moesin activa-
tion, we performed dose-response curves of moesin phos-
phorylation with the four compounds by quantitatively
analysing Thr558-phosphorylated moesin bands intensi-
ties with a chemiluminescence digital acquisition system.
Table 1: Membrane modifications after hormone treatments in different breast cancer cell lines
Treatment (15 min) Mean membrane 
thickness (pixel ± 
SD)(× 1000)
Mean membrane 
intensity (mean gray 
level ± SD)
Mean cytosol intensity 
(mean gray level ± SD)
% cells with actin 
modifications
T47-D CON 32.4 ± 5.8 61.5 ± 8.3 59.8 ± 5.6 5.2 ± 0.8 %
P 62.3 ± 9.2* 102.2 ± 10.4* 62.3 ± 7.4 64.5 ± 5.4 % *
P+E2 78.2 ± 10.3* 124.5 ± 13.2* 58.5 ± 6.1 72.2 ± 5.7 % *
MPA 76.3 ± 14.6* 118.6 ± 12.7* 67.8 ± 8.2 69.6 ± 6.1 % *
MPA+E2 92.5 ± 12.3* 131.8 ± 12.4* 57.4 ± 6.6 81.8 ± 4.9 % *
DRSP 54.6 ± 6.7 * 87.2 ± 8.3 * 61.6 ± 8.2 60.4 ± 4.4 % *
DRSP+E2 60.3 ± 5.2 * 98.5 ± 11.6* 57.8 ± 6.7 68.1 ± 5.2 % *
NES 71.5 ± 8.6* 110.2 ± 14.4 * 61.4 ± 8.5 69.6 ± 6.5 % *
NES+E2 80.6 ± 10.5 * 127.3 ± 7.2 * 59.1 ± 5.4 73.1 ± 5.6 % *
MCF-7 CON 46.6 ± 4.7 77.8 ± 5.8 74.3 ± 6.2 6.7 ± 1.3 %
P 99.2 ± 7.4 * 132.4 ± 8.6 * 68.5 ± 4.7 70.6 ± 7.4 % *
P+E2 115.8 ± 8.3 * 140.3 ± 10.2 * 66.3 ± 5.2 68.3 ± 6.2 % *
MPA 108.4 ± 11.3 * 142.7 ± 12.5 * 60.4 ± 5.6 78.2 ± 7.8 % *
MPA+E2 123.6 ± 10.8 * 150.2 ± 14.6 * 62.5 ± 4.9 80.5 ± 7.2 % *
MDA-MB-468 CON 31.2 ± 4.4 66.8 ± 7.2 62.6 ± 5.5 5.4 ± 0.7 %
P 34.3 ± 4.1 70.5 ± 6.4 64.2 ± 5.8 4.8 ± 0.6 %
P+E2 32.5 ± 3.9 68.1 ± 5.8 61.4 ± 4.3 5.1 ± 0.4 %
MPA 36.2 ± 5.2 67.2 ± 5.5 70.5 ± 5.3 4.4 ± 0.8 %
MPA+E2 32.2 ± 4.6 63.6 ± 6.2 66.3 ± 5.6 5.2 ± 0.7 %
MDA-MB-468 
(transfected with PR)
CON 34.6 ± 4.3 65.4 ± 6.8 70.4 ± 5.2 5.2 ± 0.9 %
P 66.7 ± 6.8 * 97.4 ± 8.3 * 66.3 ± 4.8 58.6 ± 6.7 % *
P+E2 72.5 ± 7.1 * 106.3 ± 10.6 * 72.5 ± 6.4 60.3 ± 6.9 % *
MPA 70.4 ± 7.4 * 102.8 ± 11.8 * 68.2 ± 5.5 60.2 ± 6.6 % *
MPA+E2 76.2 ± 8.2 * 118.5 ± 13.2 * 71.8 ± 6.8 65.8 ± 7.1 % *
The table displays the mean thickness of the cell membrane, the mean actin intensity of the membrane and of the cytoplasm, as well as the % cells 
with spatial actin modifications in several breast cancer cell lines treated with different regimens of hormones (P, MPA, DRSP, all 100 nM; NES, 1 
nM; E2, 10 nM) for 15 min. Analytic results were obtained by using Leica QWin image analysis and processing software.BMC Cancer 2008, 8:166 http://www.biomedcentral.com/1471-2407/8/166
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As shown in Fig 5B, MPA was consistently more potent in
inducing moesin activation as compared to P and DRSP.
DRSP was significantly less effective than P or MPA (Fig.
5B). As expected, the dose-response curve of NES was
shifted to the left by two orders of magnitude compared
with P, MPA or DRSP (Fig 5B). However, if bio-equivalent
concentrations are compared (1 nM NES vs. 100 nM P or
0.1 nM NES vs. 10 nM P), NES shows comparable effects
on moesin as P, being less active than MPA (Fig 5B).
Effects of progestins on actin remodeling in the presence of E2 Figure 2
Effects of progestins on actin remodeling in the presence of E2. T47-D cells were treated with E2 (10 nM) or E2 (10 
nM) plus P, MPA, DRSP (all 100 nM) or NES (1 nM) for 10 or 15 minutes, in the presence or absence of the pure PR antagonist 
ORG 31710 (ORG – 1 μM) and the pure ER antagonist ICI 182,780 (100 nM). Yellow arrows indicate longitudinal actin fibers, 
green arrows show pseudopodia, light blue arrows indicate ruffles. Nuclei are counterstained in blue.
CON E2 10’ E2 15’ E2 + I CI
CON P+ E2 10’ P+ E2 15’ P+ E2 + ORG
CON MPA+E2 15’ MPA+E2 +ORG
CON DRSP+E2 10’ DRSP+E2 15’ DRSP+E2 +ORG
CON NES+E2 10’ NES+E2 15’ NES+E2 +ORG
P+ E2 + I CI
MPA+E2 +ICI
DR S P +E 2 +IC I
NES+E2 +ICI
MPA+E2 10’
E2 + ORGBMC Cancer 2008, 8:166 http://www.biomedcentral.com/1471-2407/8/166
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Signaling mechanisms of DRSP and NES to moesin
We recently identified that natural P triggers moesin phos-
phorylation through a PRA/Gα13/RhoA/Rho-associated
kinase (ROCK) pathway, while MPA recruits a PR/Src/
phosphatidylinositol-3-kinase (PI3K)/RhoA/ROCK cas-
cade (X.D. Fu et al, submitted). Moesin phosphorylation
induced by DRSP (100 nM) or NES (1 nM) was prevented
by the PR antagonist ORG 31710 (1 μM), by the G protein
inhibitor pertussis toxin (PTX – 100 ng/mL) and by Y-
27632 (10 μM), a specific inhibitor of ROCK-2, which is
a known activator of moesin (Fig. 5C–D). However, dis-
tinct from the signaling pathways exploited by P and
MPA, the MAPK inhibitor PD98059 (5 μM) and the PI3K
inhibitor wortmannin (30 nM) also interfered with
moesin activation by DRSP (100 nM) and NES (1 nM)
(Fig. 5C–D), suggesting that MAPK and PI3K play a role in
moesin activation by these progestins, and supporting the
concept that each progestin might recruit partly distinct
PR-dependent signaling cascades.
Comparative effects of P, MPA, DRSP and NES on moesin 
activation in the presence of E2
Estrogen signals to moesin through rapid, extra-nuclear
signaling [20]. Moesin phosphorylation was slightly
increased by the addition of E2 (10 nM) to each progestin
compared to the progestins alone, although this was not
statistically significant (Fig. 6A–C). Interestingly, the PR
antagonist ORG 31710 (1 μM) inhibited the combined
effect of E2 associated with each progestin on moesin (Fig.
6A–C).
Comparative effects of P, MPA, DRSP and NES on breast 
cancer cell migration and invasion
Our recent observation indicates that P and MPA promote
T47-D cell horizontal migration through a complex cas-
cade requiring PR, G proteins, MAPK, PI3K and the Rho-
associated kinase, ROCK-2 (X.D. Fu et al, submitted).
DRSP (100 nM) and NES (1 nM) increased T47-D cell
migration, alike (Fig. 7A–D). DRSP- or NES-promoted cell
migration were reduced by ORG 31710 (1 μM), by PTX
(100 ng/mL), by the MAPK inhibitor PD98059 (5 μM), by
the PI3K inhibitor wortmannin (30 nM) and by the
ROCK inhibitor Y-27632 (10 μM) (Fig. 7A–D).
We next compared the potency of these progestins on
breast cancer cell migration. Among the tested com-
pounds, MPA (100 nM) was the most potent, increasing
cell migration by 54% compared to control (Fig. 8A–E). P
(100 nM), DRSP (100 nM) and NES (1 nM) increased
T47-D horizontal migration vs. control by 37%, 32% and
26% (Fig. 8A–E), respectively, which agrees with the order
they rank on moesin activation.
MCF-7 cells and MDA-MB-468 cells with or without PR transfection were treated with P and MPA (both 100 nM), in the pres- ence or absence of E2 (10 nM) Figure 3
MCF-7 cells and MDA-MB-468 cells with or without PR transfection were treated with P and MPA (both 100 
nM), in the presence or absence of E2 (10 nM). Yellow arrows indicate longitudinal actin fibers, green arrows show pseu-
dopodia, light blue arrows indicate ruffles. Nuclei are counterstained in blue.
MCF-7
MDA-MB-468
MDA-MB-468 
(Transfected 
with PR)
CON P MPA E2+ P E2+ MPA
CON P MPA E2+ P E2+ MPA
CON P MPA E2+ P E2+ MPABMC Cancer 2008, 8:166 http://www.biomedcentral.com/1471-2407/8/166
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In order to check for the requirement of moesin for pro-
gestins-promoted cell migration we silenced moesin with
antisense oligonucleotides (PONs) (Fig 8A, 8B, 8E).
Transfection with moesin antisense PONs greatly reduced
the action of both progesterone and MPA on cell migra-
tion, while sense PONs had no impact (Fig. 8A, 8B, 8E).
E2 promoted T47-D cell migration as well. However, no
significant additive effects were found during co-treat-
ment with any of the progestins. Interestingly, the PR
antagonist ORG31710 (1 μM) significantly reduced cell
migration associated with the four tested progestins both
in the absence and in the presence of E2 (Fig. 8A–E).
Finally, we investigated the actions of the four progestins
on breast cancer cell invasion of a three-dimensional
matrix (matrigel). P, MPA, DRSP (all 100 nM) and NES (1
nM) all enhanced cell invasive behavior (Fig. 9). Consist-
ently with the previous findings, the invasion indexes
indicate that MPA is more effective compared to the other
compounds (invasion index 4.68). Treatment with P, NES
and DRSP resulted in invasion indexes of 3.91, 3.73 and
3.49, respectively. E2 (10 nM) was more potent than the
progestins in driving breast cancer cell invasion of the
matrix. When T47-D cells were exposed to E2 plus P,
DRSP or NES the invasion indexes turned out to be signif-
icantly reduced vs. treatment with E2 alone. The addition
of MPA to E2 also resulted in a reduction of the invasion
index below that of E2 alone, but this did not reach statis-
tical significance (Fig. 9).
Discussion
The role of progestins on breast cancer development or
progression is controversial [23]. A variety of progestins
are currently used in postmenopausal HRT and circum-
stantial evidence from recent clinical trials suggests that
each compound may differently contribute to the risk of
developing breast cancer [5]. However, limited informa-
tion is available on the impact of progestins on breast can-
cer progression.
The present work shows that four different progestins,
including natural progesterone, the synthetic progestin
MPA, and two newer progestins, DRSP and NES, all
enhance PR+ breast cancer cell migration and invasion in
vitro. These effects are coupled to the activation of the
Progestins activate moesin Figure 4
Progestins activate moesin. (A-H) show total cell amount of wild-type moesin or Thr558-phosphorylated moesin (P-
Moesin) in cells treated with the indicated progestins at different time points or concentrations.
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Comparative effects of different progestin on moesin activation Figure 5
Comparative effects of different progestin on moesin activation. (A) T47-D breast cancer cells were treated with E2 
(10 nM) or progestins (P, MPA, DRSP all 100 nM; NES, 1 nM) for 15 min and total cell amount of Moesin or P-Moesin are 
shown. (B) Shows the concentration/effect curve of each progestin on moesin phosphorylation over a range of concentrations. 
* = P < 0.05 vs. DRSP at the same concentration. (C-D) Cells were exposed to DRSP (100 nM) or NES (1 nM) for 15 min, in 
the presence or absence of the pure PR antagonist ORG 31710 (ORG – 1 μM), of the MEK inhibitor PD98059 (PD – 5 μM) or 
of the PI3K inhibitor wortmannin (WM – 30 nM), of the G protein inhibitor, PTX (100 ng/mL) or of the ROCK-2 inhibitor Y-
27632 (10 μM). Total cell amounts of Moesin or P-Moesin are shown.
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actin-binding protein moesin, which drives actin fibers to
the cell membrane, increasing the formation of special-
ized membrane structures which interact with the extra-
cellular matrix and with nearby cells, thus allowing the
cells to achieve locomotion.
The control of intracellular actin organization by pro-
gestins represents an original mechanism through which
these hormonal compounds may alter the ability of breast
cancer cells to move. This adds to the previously reported
effects of progesterone on breast cancer cell invasion
through tyrosine phosphorylation of focal adhesion
kinase [24], through increased tissue factor gene expres-
sion or glucose uptake [25,26], or through the activation
of matrix metalloproteinases and urokinase-type plas-
minogen activator [27]. These findings, along with ours,
identify potential targets for the development of drugs
against breast cancer progression linked to steroids, partic-
ularly endogenous or exogenous progestogens.
Progestins exert their biological functions principally by
binding to PR [28]. In the present study, the pure PR
antagonist ORG 31710 blocks moesin activation, cell
migration and invasion induced by all four compounds,
supporting the central role of PR in these processes. In
agreement, PR negative cell lines show actin remodeling
in response to progestins only after transfection with PR.
However, the spectrum of promiscuous binding to other
steroid receptors varies significantly among progestins,
leading to variable cellular effects. In addition to this, dis-
tinct signaling pathways can be recruited by PRs in the
presence of different ligands. We recently showed that P
and MPA induce the recruitment of partially distinct sign-
aling cascades in endothelial cells acting on PRs [29] and
DRSP and NES promote T47-D breast cancer cell horizontal migration Figure 7
DRSP and NES promote T47-D breast cancer cell horizontal migration. (A-B) Cells were treated with DRSP (100 
nM) or NES (1 nM) for 48 h, in the presence or absence of ORG 31710 (ORG – 1 μM), of PD98059 (PD – 5 μM), of wortman-
nin (WM – 30 nM), of PTX (100 ng/mL) or of Y-27632 (Y – 10 μM). T47-D cells were scraped out of the cell culture dish and 
the extent of migration of the remaining cells was assayed in non-proliferating cells in the presence of Ara-C. Representative 
images of cell migration are shown. (C-D) Cell migration distances were measured and values are presented as % of control. * 
= P < 0.05 vs. control; # = P < 0.05 vs. DRSP or NES; The experiments were performed in triplicates and data representing the 
migration distance of cells from the starting line are expressed as mean ± SD.
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Effects of progestins in combination with E2 on T47-D breast cancer cell migration Figure 8
Effects of progestins in combination with E2 on T47-D breast cancer cell migration. (A-D) Cells were treated with 
the progestins (P, MPA, DRSP all 100 nM; NES, 1 nM) alone or in combination with E2 (10 nM) for 48 h, in the presence or 
absence of ORG 31710 (ORG – 1 μM). Other cells were transfected with moesin antisense phosphorotioate oligonucleotides 
(PON) (AS, antisense – 2 μM) or sense PON (S, sense – 2 μM). T47-D cells were scraped out of the cell culture dish and the 
extent of migration of the remaining cells was assayed in non-proliferating cells in the presence of Ara-C. Representative 
images of cell migration are shown. (E) Cell migration distances were measured and values are presented as % of control. * = P 
< 0.05 vs. the corresponding progestin alone; # = P < 0.05 vs. E2 + the corresponding progestin without ORG; † = P < 0.05 vs. 
E2.
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we recently identified similar differences in breast cancer
cells (Fu XD, et al. submitted). Our present findings
strengthen this concept, suggesting that depending on the
ligand, PRs may be driven to recruit different signal trans-
duction pathways to accomplish multiple functions in
human cells.
The progestational potency of each compound is usually
compared by identifying the dose associated with full
endometrial transformation and ovulation inhibition in
animals [2]. However, the real progestogenic activity
depends on a variety of factors, including the route and
timing of administration and the specific endpoint tested,
such that it is difficult to definitely establish the most
appropriate concentration to compare two progestins. In
the present study, we performed concentration-depend-
ence curves to better compare the effects of these pro-
gestins over a wider range of concentrations on some of
the investigated targets. Our results indicate that the order
of potency for the studied actions in T47-D breast cancer
cells is MPA > P > DRSP. Given the fact that NES is 100
times more effective than P in transforming the
endometrium and in binding PRs [11], we selected a 100-
time lower concentration for comparative analyses. When
comparing these concentrations, NES exerts effects which
are comparable to those of P on moesin activation. Over-
all, these findings suggest that markers of biological/func-
tional effect, such as moesin activation or cell migration
and invasion might be of relevance to better characterize
the comparative actions of progestins in pre-clinical set-
tings.
Interestingly, our findings show that the combination of
P, DRSP or NES with E2 turns into a significant decrease
of cell invasion vs. E2 alone. This is not found for the com-
bination of MPA with E2. However, this interference with
estrogen-dependent cell invasion displayed by P, NES and
DRSP is not related to the regulation of moesin or of the
actin cytoskeleton. These findings suggest that, notwith-
standing that both estrogen and progestins promote T47-
D breast cancer cell migration and invasion, some pro-
gestins partially offset the effect of E2 on ER+/PR+ breast
cancer cell invasion, but also that this does not extend to
all PR ligands.
This apparent discrepancy could be ascribed to the differ-
ent molecular actions of sex steroids involved in these
processes [30]. Indeed, moesin activation and actin
remodeling are recruited though rapid, extra-nuclear sign-
aling pathways of ER and PR, while the regulatory effects
Progestins alone or in combination with E2 promote T47-D breast cancer cell invasion Figure 9
Progestins alone or in combination with E2 promote T47-D breast cancer cell invasion. Cells were treated with 
the progestins alone (P, MPA, DRSP all 100 nM; NES, 1 nM) or in combination with E2 (10 nM) for 24 h and cell invasion was 
assayed with matrigel invasion assays. Invading cells were counted in three different central fields of triplicate membranes. Inva-
sion indexes and representative images are shown. * = P < 0.01 vs. control; # = P < 0.05 vs. E2.
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on cell migration and invasion likely derive from complex
integrations of nongenomic and genomic actions. Indeed,
the recruitment of ER and PR each turns into the regula-
tion of a complex subset of target genes, whose function
on cell movement or invasion is not yet investigated.
Moreover, recent findings indicate that PR may act as an
ER antagonist in certain circumstances, altering the ability
of ER to interact with estrogen response elements and to
trigger gene expression [31].
Blockade of PR with ORG 31710 inhibits moesin activa-
tion and cell migration induced by the combination of E2
with each progestin. A similar observation has already
been reported in breast cancer cells, where the up-regula-
tion of breast cancer resistance protein expression induced
by the combination of E2 plus progesterone is abolished
by the progesterone receptor antagonist RU486 [32]. One
possible explanation of this observation could be that PR
and ER need to be cross-coupled to induce this action, and
that the presence of a PR agonist might facilitate this phe-
nomenon. On the opposite, the presence of the PR antag-
onist may interfere with the ability of PR to interact with
ER, thus antagonizing the function of both ER and PR.
This would be consistent with the established ability of
the ER antagonist ICI 182,780 to block PR signaling in
breast cancer cells [33] but additional studies will be nec-
essary to provide a definitive answer.
Conclusion
Taken together, our findings show that P, MPA, DRSP and
NES alone or in combination with E2 increase breast can-
cer cell migration and invasion through the functional
modulation of the actin-binding protein moesin and the
induction of dynamic rearrangements of the actin
cytoskeleton. This suggests that progestins may have an
impact on the progression of PR+ breast cancer by altering
the ability of cancer cells to interact with the extracellular
environment and to eventually move or invade the sur-
rounding environment. The potency of the progestins on
these targets is however different, with maximal effects
induced by MPA, followed by P, NES and DRSP. These dif-
ferences in biological efficacy are possibly related to par-
tially discrepant recruitment of extra-nuclear signaling
pathways by PR in the presence of each progestin. All
together, these findings provide evidence that PR activa-
tion might play a role in the progression of ER+/PR+
breast cancers.
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